Zymewire is the closest thing Arcova has to a direct neighbor: both focus on life science, both monitor company activity, and both help teams prioritize accounts. Zymewire combines human-verified updates, company segmentation, contact data, stealth-company discovery, and Salesforce workflows. Arcova applies a customer-specific ICP and company-level readiness model to life science public-record evidence. The difference is the scoring lens and workflow, not whether either product can prioritize.
What does Zymewire actually do?
Zymewire describes itself as a sales intelligence platform for teams serving biotech and pharma, and reports serving more than 400 clients, including many of the largest CROs and contract manufacturers. Its core mechanics, as Zymewire presents them: real-time updates about companies you care about, segmentation of company lists across more than 150 data points, verified contact information, and discovery of industry newcomers and stealth companies, with an AI pipeline that scans thousands of documents a day and a dedicated data team verifying what it surfaces. Zymewire's official site also describes Salesforce integration and its Zoudini product, which syncs selected intelligence into Salesforce and supports prioritization by funding, therapeutic focus, and clinical-trial activity.
That is a broad offering: a curated stream of life science updates, flexible list filtering and prioritization, contact data, and a CRM workflow. It is inaccurate to reduce Zymewire to an alert feed.
What does Arcova do differently?
Arcova's distinction is its customer-specific scoring model. You define an ICP and Arcova scores accounts for fit using attributes such as therapeutic area, modality, and development stage. Public activity, including funding, trial milestones, regulatory decisions, conference activity, and hiring, is then read as buying signals and rolled into a company-level readiness score with supporting evidence. Zymewire also filters and prioritizes accounts; Arcova's narrower claim is that its ranking is tied to your ICP and its life science readiness model.
Contact data follows the same logic. Arcova does contact discovery, screening companies against your ICP before sourcing contacts, so a team spends on contacts at accounts already worth working rather than enriching first and qualifying afterward.
| Zymewire | Arcova | |
|---|---|---|
| What it is | Life science sales intelligence, company data, contacts, and alerts | Life science fit and readiness layer on your account list |
| Primary output | Filtered and prioritized lists plus human-verified updates | Accounts scored against your ICP and readiness model |
| Contact data | Verified contact information on tracked companies | Contact discovery, screened against your ICP before sourcing |
| Stealth-company discovery | A named strength: industry newcomers and stealth companies | Focused on scoring and timing the accounts on your list |
| CRM | Salesforce integration and automated intelligence sync | Works with the stack you already run |
| Pricing | Contact Zymewire for current plan pricing | Free to start |
When is Zymewire the better fit?
If your motion is built around discovering companies you do not know yet, especially stealth-mode and newly formed biotechs before they reach the mainstream databases, that is a capability Zymewire has invested in specifically and names as a strength. The same goes for a large, Salesforce-centric enterprise sales organization that wants a long-established vendor with a dedicated human data team behind every alert: Zymewire has been doing exactly that for years, at scale, for many of the biggest service providers in the industry. And if your reps genuinely prefer working from a curated event stream, deciding for themselves what each update means, an alert-first product matches that style better than a score-first one.
Related comparisons
See how Arcova compares to SciLeads, ZoomInfo, and building it in-house as well.